Literature DB >> 23688779

ADAM17 silencing by adenovirus encoding miRNA-embedded siRNA revealed essential signal transduction by angiotensin II in vascular smooth muscle cells.

Katherine J Elliott1, Allison M Bourne, Takehiko Takayanagi, Akira Takaguri, Tomonori Kobayashi, Kunie Eguchi, Satoru Eguchi.   

Abstract

Small interfering RNA (siRNA) mediated gene silencing has been utilized as a powerful molecular tool to study the functional significance of a specific protein. However, due to transient gene silencing and insufficient transfection efficiency, this approach can be problematic in primary cell culture such as vascular smooth muscle cells. To overcome this weakness, we utilized an adenoviral-encoded microRNA (miRNA)-embedded siRNA "mi/siRNA"-based RNA interference. Here, we report the results of silencing a disintegrin and metalloprotease 17 (ADAM17) in cultured rat vascular smooth muscle cells and its functional mechanism in angiotensin II signal transduction. 3 distinct mi/siRNA sequences targeting rat ADAM17 were inserted into pAd/CMV/V5-DEST and adenoviral solutions were obtained. Nearly 90% silencing of ADAM17 was achieved when vascular smooth muscle cells were infected with 100 multiplicity of infection of each ADAM17 mi/siRNA encoding adenovirus for 3days. mi/siRNA-ADAM17 but not mi/siRNA-control inhibited angiotensin II-induced epidermal growth factor receptor trans-activation and subsequent extracellular signal-regulated kinase activation and hypertrophic response in the cells. mi/siRNA-ADAM17 also inhibited angiotensin II-induced heparin-binding epidermal growth factor-like factor shedding. This inhibition was rescued with co-infection of adenovirus encoding mouse ADAM17 but not by its cytosolic domain deletion mutant or cytosolic Y702F mutant. As expected, angiotensin II induced tyrosine phosphorylation of ADAM17 in the cells. In conclusion, ADAM17 activation via its tyrosine phosphorylation contributes to heparin-binding epidermal growth factor-like factor shedding and subsequent growth promoting signals induced by angiotensin II in vascular smooth muscle cells. An artificial mi/siRNA-based adenoviral approach appears to be a reliable gene-silencing strategy for signal transduction research in primary cultured vascular cells.
Copyright © 2013 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  ADAM17; Angiotensin II type 1 receptor; Epidermal growth factor receptor; Signal transduction; Vascular biology

Mesh:

Substances:

Year:  2013        PMID: 23688779      PMCID: PMC3735780          DOI: 10.1016/j.yjmcc.2013.05.005

Source DB:  PubMed          Journal:  J Mol Cell Cardiol        ISSN: 0022-2828            Impact factor:   5.000


  38 in total

Review 1.  ADAMs: key components in EGFR signalling and development.

Authors:  Carl P Blobel
Journal:  Nat Rev Mol Cell Biol       Date:  2005-01       Impact factor: 94.444

2.  A lentiviral microRNA-based system for single-copy polymerase II-regulated RNA interference in mammalian cells.

Authors:  Frank Stegmeier; Guang Hu; Richard J Rickles; Gregory J Hannon; Stephen J Elledge
Journal:  Proc Natl Acad Sci U S A       Date:  2005-09-01       Impact factor: 11.205

3.  Adenovirus-based short hairpin RNA vectors containing an EGFP marker and mouse U6, human H1, or human U6 promoter.

Authors:  Seungil Ro; Sung Jin Hwang; Tamás Ordög; Kenton M Sanders
Journal:  Biotechniques       Date:  2005-04       Impact factor: 1.993

4.  Signal-crosstalk between Rho/ROCK and c-Jun NH2-terminal kinase mediates migration of vascular smooth muscle cells stimulated by angiotensin II.

Authors:  Haruhiko Ohtsu; Mizuo Mifune; Gerald D Frank; Shuichi Saito; Tadashi Inagami; Shokei Kim-Mitsuyama; Yoh Takuwa; Terukatsu Sasaki; Jeffrey D Rothstein; Hiroyuki Suzuki; Hidekatsu Nakashima; Elethia A Woolfolk; Evangeline D Motley; Satoru Eguchi
Journal:  Arterioscler Thromb Vasc Biol       Date:  2005-06-30       Impact factor: 8.311

5.  Post-transcriptional up-regulation of ADAM17 upon epidermal growth factor receptor activation and in breast tumors.

Authors:  Belén Santiago-Josefat; Cary Esselens; Joan Josep Bech-Serra; Joaquín Arribas
Journal:  J Biol Chem       Date:  2007-01-16       Impact factor: 5.157

6.  Artificial microRNAs as siRNA shuttles: improved safety as compared to shRNAs in vitro and in vivo.

Authors:  Ryan L Boudreau; Inês Martins; Beverly L Davidson
Journal:  Mol Ther       Date:  2008-11-11       Impact factor: 11.454

7.  Caveolin-1 negatively regulates a metalloprotease-dependent epidermal growth factor receptor transactivation by angiotensin II.

Authors:  Akira Takaguri; Heigoro Shirai; Keita Kimura; Akinari Hinoki; Kunie Eguchi; MaryEllen Carlile-Klusacek; Baohua Yang; Victor Rizzo; Satoru Eguchi
Journal:  J Mol Cell Cardiol       Date:  2010-12-21       Impact factor: 5.000

8.  Angiotensin II induces hypertrophy, not hyperplasia, of cultured rat aortic smooth muscle cells.

Authors:  A A Geisterfer; M J Peach; G K Owens
Journal:  Circ Res       Date:  1988-04       Impact factor: 17.367

9.  Tumor necrosis factor-alpha-converting enzyme is a key regulator of agonist-induced cardiac hypertrophy and fibrosis.

Authors:  Xiang Wang; Tatsujiro Oka; Fung L Chow; Stephan B Cooper; Jeff Odenbach; Gary D Lopaschuk; Zamaneh Kassiri; Carlos Fernandez-Patron
Journal:  Hypertension       Date:  2009-07-06       Impact factor: 10.190

10.  Direct activation of RhoA by reactive oxygen species requires a redox-sensitive motif.

Authors:  Amir Aghajanian; Erika S Wittchen; Sharon L Campbell; Keith Burridge
Journal:  PLoS One       Date:  2009-11-26       Impact factor: 3.240

View more
  18 in total

1.  Vascular ADAM17 as a Novel Therapeutic Target in Mediating Cardiovascular Hypertrophy and Perivascular Fibrosis Induced by Angiotensin II.

Authors:  Takehiko Takayanagi; Steven J Forrester; Tatsuo Kawai; Takashi Obama; Toshiyuki Tsuji; Katherine J Elliott; Elisa Nuti; Armando Rossello; Hang Fai Kwok; Rosario Scalia; Victor Rizzo; Satoru Eguchi
Journal:  Hypertension       Date:  2016-08-01       Impact factor: 10.190

2.  Caveolin-1 Deletion Prevents Hypertensive Vascular Remodeling Induced by Angiotensin II.

Authors:  Steven J Forrester; Katherine J Elliott; Tatsuo Kawai; Takashi Obama; Michael J Boyer; Kyle J Preston; Zhen Yan; Satoru Eguchi; Victor Rizzo
Journal:  Hypertension       Date:  2016-11-28       Impact factor: 10.190

Review 3.  AT1 receptor signaling pathways in the cardiovascular system.

Authors:  Tatsuo Kawai; Steven J Forrester; Shannon O'Brien; Ariele Baggett; Victor Rizzo; Satoru Eguchi
Journal:  Pharmacol Res       Date:  2017-05-17       Impact factor: 7.658

Review 4.  Angiotensin II Signal Transduction: An Update on Mechanisms of Physiology and Pathophysiology.

Authors:  Steven J Forrester; George W Booz; Curt D Sigmund; Thomas M Coffman; Tatsuo Kawai; Victor Rizzo; Rosario Scalia; Satoru Eguchi
Journal:  Physiol Rev       Date:  2018-07-01       Impact factor: 37.312

5.  Caveolin 1 is critical for abdominal aortic aneurysm formation induced by angiotensin II and inhibition of lysyl oxidase.

Authors:  Takehiko Takayanagi; Kevin J Crawford; Tomonori Kobayashi; Takashi Obama; Toshiyuki Tsuji; Katherine J Elliott; Tomoki Hashimoto; Victor Rizzo; Satoru Eguchi
Journal:  Clin Sci (Lond)       Date:  2014-06       Impact factor: 6.124

6.  Role of epidermal growth factor receptor and endoplasmic reticulum stress in vascular remodeling induced by angiotensin II.

Authors:  Takehiko Takayanagi; Tatsuo Kawai; Steven J Forrester; Takashi Obama; Toshiyuki Tsuji; Yamato Fukuda; Katherine J Elliott; Douglas G Tilley; Robin L Davisson; Joon-Young Park; Satoru Eguchi
Journal:  Hypertension       Date:  2015-04-27       Impact factor: 10.190

7.  Vascular induction of a disintegrin and metalloprotease 17 by angiotensin II through hypoxia inducible factor 1α.

Authors:  Takashi Obama; Takehiko Takayanagi; Tomonori Kobayashi; Allison M Bourne; Katherine J Elliott; Martine Charbonneau; Claire M Dubois; Satoru Eguchi
Journal:  Am J Hypertens       Date:  2014-05-28       Impact factor: 2.689

Review 8.  Understanding Angiotensin II Type 1 Receptor Signaling in Vascular Pathophysiology.

Authors:  Satoru Eguchi; Tatsuo Kawai; Rosario Scalia; Victor Rizzo
Journal:  Hypertension       Date:  2018-03-26       Impact factor: 10.190

9.  Epidermal Growth Factor Receptor Transactivation: Mechanisms, Pathophysiology, and Potential Therapies in the Cardiovascular System.

Authors:  Steven J Forrester; Tatsuo Kawai; Shannon O'Brien; Walter Thomas; Raymond C Harris; Satoru Eguchi
Journal:  Annu Rev Pharmacol Toxicol       Date:  2015-11-09       Impact factor: 13.820

10.  Clinical Relevance and Role of Neuronal AT1 Receptors in ADAM17-Mediated ACE2 Shedding in Neurogenic Hypertension.

Authors:  Jiaxi Xu; Srinivas Sriramula; Huijing Xia; Lisa Moreno-Walton; Frank Culicchia; Oliver Domenig; Marko Poglitsch; Eric Lazartigues
Journal:  Circ Res       Date:  2017-05-16       Impact factor: 17.367

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.